Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (ticker: DMIIU) is a blank-check company targeting the domestic pharmaceutical manufacturing and life sciences sector. The company filed an S-1/A registration amendment with the SEC on September 16, 2025, continuing its pre-IPO registration process. The "II" designation indicates this is the sponsor's second SPAC vehicle in the Drugs Made In America series, reflecting a sustained strategic focus on U.S.-based drug production and domestic pharma deal flow. The offering remained in active registration as of the filing date, with the IPO process ongoing in 2025. Sign up at SpacDesk for the full deal profile, sponsor details, and real-time filing alerts on DMIIU and the broader SPAC market.